米托蒽醌治疗急性白血病的疗效分析

Therapeutic Analysis of Mitoxantone in Acute Leukemia

目的：观察米托蒽醌治疗急性白血病的疗效及毒副作用。方法：对我院46例急性白血病随机分为两组。试验组28例,采用MA方案（米托蒽醌6~8mg/m2,第1~3天,Ara-C 100mg/m2,第1~7天）,或MVP方案（米托蒽醌6~8mg/m2第1,2,3,15,22天,长春新碱2 mg第1,8,15,22天,泼尼松40mg/m2,第1~28天）治疗急性非淋巴细胞白血病（ANLL）和急性淋巴细胞白血病（ALL）。对照组18例,采用DA方案（柔红霉素40mg/m2第1~3天,Ara-C 100mg/m2第1~7天）,或DVP方案（柔红霉素40mg/m2第1,2,3,15,22天,长春新碱2mg第1,8,15,22天,泼尼松40mg/m2,第1~28天）治疗ANLL和ALL。结果：实验组总有效率82.1%,完全缓解率57.1%。对照组总有效率66.7%,完全缓解率38.9%。米托蒽醌的主要毒副作用为骨髓抑制和胃肠道反应。结论：MA或MVP方案是治疗急性白血病的有效方案之一,该方案可明显提高急性白血病的缓解率。

Objective：To observe the curative effect and side effects of Mitoxantrone（MTN）in treatment of acute leukemia.Methods：46 cases of patients with acute leukemia were randomly divided into MTN and control groups.The 28 cases of MTN group were treated by MA regimen（MTN 6-8 mg/m2 day 1 to day 3 and Ara-C 100 mg/m2 day 1 to day 7）for ANLL,or treated by MVP regimen（MTN 6-8 mg/m2 day 1 to day 3,VCR 2 mg day 1,8,15,22,and Prednisone 40 mg/m2 day 1-28）for ALL.18 cases of control group was treated by DA regimen（DNR 40 mg/m2 day 1 to day 3 and Ara-C 100 mg/m2 day 1 to day 7）for ANLL,or DVP regimen（DNR 40 mg/m2 day 1 to day 3,VCR 2 mg day 1,8,15,22,and Prednisone 40 mg/m2 day 1-28）for ALL.Results：the total efficiency of MTN group was 82.1% and the complete remissiom（CR）rate was 57.1%.The total efficiency and CR of the control group was 66.7% and 38.9% respectively.Main sides effects were bone marrow suppression and gastrointestinal reaction.Conclusion：MA or MVP regimen is one of the effective scheme in treatment of acute leukemia and can be healpful to increase CR rate.